European Supplementary Protection Certificates (SPCs) for Pharmaceuticals – A Practical Guide

Companies carrying out pharmaceutical research will be aware of patent protection, but perhaps less so of other forms of intellectual property rights (IPRs) that compliment patents.

Supplementary Protection Certificates (SPCs) are linked to a granted patent, and are available across Europe. Once granted, SPCs provide additional protection for a marketable pharmaceutical or agricultural product once the related patent has expired. Whilst SPCs require patent protection to have existed, they are a separate right, and are an invaluable way of extending market exclusivity for a marketable medicinal product

Companies looking to take a pharmaceutical product to market in Europe, either themselves or in collaboration with a partner, should consider SPCs as part of their IP strategy.

Our helpful guide covers:

  • The reason for SPCs
  • What is the scope of an SPC?
  • What is the duration of an SPC?
  • What are the requirements for an SPC?
  • UK SPCs and BREXIT
  • Lipitor case study: potential impact of an SPC

You can access our guide in PDF format here: European Supplementary Protection Certificates (SPCs) for Pharmaceuticals – A Practical Guide.

Get in touch

If you are an ambitious business and you expect an IP service provider that can understand and help you achieve your commercial objectives, then we want to work with you. Complete the enquiry form below and one of our specialists will be in touch within one working day. Alternatively you can call us on +44 (0)20 7655 8500. We look forward to hearing from you.